PharmaCyte Biotech (PMCB) Non-Current Deferred Tax Liability (2024 - 2025)
PharmaCyte Biotech (PMCB) posted quarterly Non-Current Deferred Tax Liability of $1.7 million for Q2 2025, up 62.38% year-over-year from $1.0 million in Q2 2024, and up 62.38% quarter-over-quarter from $1.0 million in Q2 2024.
PharmaCyte Biotech (PMCB) Non-Current Deferred Tax Liability (2024 - 2025) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Non-Current Deferred Tax Liability for 2 consecutive years, with $1.7 million the latest figure, recorded in Q2 2025.
- In Q2 2025, Non-Current Deferred Tax Liability rose 62.38% year-over-year to $1.7 million; the TTM figure through Apr 2025 stood at $1.7 million (up 62.38% YoY), while the FY2025 annual figure was $1.7 million, up 62.38% from the prior year.
- Non-Current Deferred Tax Liability advanced to $1.7 million in Q2 2025 per PMCB's latest filing, from $1.0 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $1.7 million in Q2 2025 and bottomed at $1.0 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2025 | 1.69 Mn |
| Apr 30, 2025 | 1.69 Mn |
| Apr 30, 2024 | 1.04 Mn |
| Apr 30, 2024 | 1.04 Mn |